Global Guaifenesin Market Is Expected To Grow At A CAGR Of 2.7% From 2020 To 2027
Guaifenesin is categorized as an expectorant which enhances the removal of phlegm and bronchial secretions by reducing the adhesiveness and viscosity of mucus. The drug strength is 200mg for tablets, 600 mg for extended-release tablets, and 100 mg/5mL for oral syrup. It is available as both prescription and over the counter product throughout the globe. Chest congestion is dominating the clinical application segment for the guaifenesin market. Respiratory tract infections such as common cold, influenza, asthma, bronchitis, allergic reactions, etc are associated with the disease manifestation of chest congestion and…
Read More